Advanced search
Publication Cover
Emerging Microbes & Infections Volume 12, 2023 - Issue 2
Submit an article Journal homepage
1,960
Views
25
CrossRef citations to date
0
Altmetric
Emerging and Re-Emerging Coronaviruses

Immune evasion and membrane fusion of SARS-CoV-2 XBB subvariants EG.5.1 and XBB.2.3

Julia N. Faraonea Center for Retrovirus Research, The Ohio State University, Columbus, OH, USA;b Department of Veterinary Biosciences, The Ohio State University, Columbus, OH, USA;c Molecular, Cellular, and Developmental Biology Program, The Ohio State University, Columbus, OH, USAView further author information
,
Panke Qua Center for Retrovirus Research, The Ohio State University, Columbus, OH, USA;b Department of Veterinary Biosciences, The Ohio State University, Columbus, OH, USAView further author information
,
Negin Goodarzia Center for Retrovirus Research, The Ohio State University, Columbus, OH, USA;b Department of Veterinary Biosciences, The Ohio State University, Columbus, OH, USAView further author information
,
Yi-Min Zhenga Center for Retrovirus Research, The Ohio State University, Columbus, OH, USA;b Department of Veterinary Biosciences, The Ohio State University, Columbus, OH, USAView further author information
,
Claire Carlind Department of Internal Medicine, Division of Cardiovascular Medicine, The Ohio State University, Columbus, OH, USAView further author information
,
Linda J. Saife Center for Food Animal Health, Animal Sciences Department, OARDC, College of Food, Agricultural and Environmental Sciences, The Ohio State University, Wooster, OH, USA;f Veterinary Preventive Medicine Department, College of Veterinary Medicine, The Ohio State University, Wooster, OH, USA;g Viruses and Emerging Pathogens Program, Infectious Diseases Institute, The Ohio State University, Columbus, OH, USAView further author information
,
Eugene M. Oltzh Department of Microbial Infection and Immunity, The Ohio State University, Columbus, OH, USAView further author information
,
Kai Xua Center for Retrovirus Research, The Ohio State University, Columbus, OH, USA;b Department of Veterinary Biosciences, The Ohio State University, Columbus, OH, USAView further author information
,
Daniel Jonesi Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH, USAView further author information
,
Richard J. Guminad Department of Internal Medicine, Division of Cardiovascular Medicine, The Ohio State University, Columbus, OH, USA;j Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, OH, USA;k Department of Physiology and Cell Biology, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USAView further author information
&
Shan-Lu Liua Center for Retrovirus Research, The Ohio State University, Columbus, OH, USA;b Department of Veterinary Biosciences, The Ohio State University, Columbus, OH, USA;g Viruses and Emerging Pathogens Program, Infectious Diseases Institute, The Ohio State University, Columbus, OH, USA;h Department of Microbial Infection and Immunity, The Ohio State University, Columbus, OH, USACorrespondence[email protected]
View further author information
 show all
Article: 2270069 | Received 05 Sep 2023, Accepted 05 Oct 2023, Published online: 26 Oct 2023

References

  • Wang Q, Guo Y, Iketani S, et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. Nature. 2022;608:603–608. doi:10.1038/s41586-022-05053-w
  • Planas D, Saunders N, Maes P, et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2022;602:671–675. doi:10.1038/s41586-021-04389-z
  • Miller J, Hachmann NP, Collier AY, et al. Substantial neutralization escape by SARS-CoV-2 Omicron variants BQ.1.1 and XBB.1. N Engl J Med. 2023;388:662–664. doi:10.1056/NEJMc2214314
  • Hachmann NP, Miller J, Collier AY, et al. Neutralization escape by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, and BA.5. N Engl J Med. 2022;387:86–88. doi:10.1056/NEJMc2206576
  • Faraone JN, Qu P, Evans JP, et al. Neutralization escape of Omicron XBB, BR.2, and BA.2.3.20 subvariants. Cell Reps Med. 2023;4:101049.
  • Evans JP, Zeng C, Qu P, et al. Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2. Cell Host Microbe. 2022;30:1093–1102.e1093. doi:10.1016/j.chom.2022.04.014
  • Qu P, Faraone JN, Evans JP, et al. Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants. Cell Rep. 2023;42:112443.
  • Cao Y, Yisimayi A, Jian F, et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature. 2022;608:593–602. doi:10.1038/s41586-022-04980-y
  • Zou J, Kurhade C, Patel S, et al. Neutralization of BA.4-BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with bivalent vaccine. N Engl J Med. 2023;388:854–857. doi:10.1056/NEJMc2214916
  • Zhang X, Chen LL, Ip JD, et al. Omicron sublineage recombinant XBB evades neutralising antibodies in recipients of BNT162b2 or CoronaVac vaccines. Lancet Microbe. 2022. doi:10.1016/s2666-5247(22)00335-4
  • Yue C, Song W, Wang L, et al. Enhanced transmissibility of XBB.1.5 is contributed by both strong ACE2 binding and antibody evasion. bioRxiv, 2023, 2023.2001.2003.522427. doi:10.1101/2023.01.03.522427.
  • Yamasoba D, Uriu K, Plianchaisuk A, et al. Virological characteristics of the SARS-CoV-2 Omicron XBB.1.16 variant. bioRxiv, 2023, 2023.2004.2006.535883. doi:10.1101/2023.04.06.535883.
  • Wang Q, Iketani S, Li Z, et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell. 2023;186:279–286.e278. doi:10.1016/j.cell.2022.12.018
  • Uraki R, Ito M, Furusawa Y, et al. Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB. Lancet Infect Dis. 2023;23:30–32. doi:10.1016/s1473-3099(22)00816-7
  • Tamura T, Ito J, Uriu K, et al. Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two omicron subvariants. Nat Commun. 2023;14:2800. doi:10.1038/s41467-023-38435-3
  • Kurhade C, Zou J, Xia H, et al. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster. Nat Med. 2022. doi:10.1038/s41591-022-02162-x
  • He Q, Wu L, Xu Z, et al. An updated atlas of antibody evasion by SARS-CoV-2 Omicron sub-variants including BQ.1.1 and XBB. Cell Rep Med. 2023;4:100991. doi:10.1016/j.xcrm.2023.100991
  • Davis-Gardner ME, Lai L, Wali B, et al. Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA bivalent booster. N Engl J Med. 2022;388:183–185. doi:10.1056/NEJMc2214293
  • Recommendation for the 2023-2024 Formula of COVID-19 vaccines in the U.S. (2023).
  • Yisimayi A, Song W, Wang J, et al. Repeated Omicron infection alleviates SARS-CoV-2 immune imprinting. bioRxiv, 2023, 2023.2005.2001.538516. doi:10.1101/2023.05.01.538516.
  • Wang Q, Guo Y, Tam AR, et al. Deep immunological imprinting due to the ancestral spike in the current bivalent COVID-19 vaccine. bioRxiv, 2023, 2023.2005.2003.539268. doi:10.1101/2023.05.03.539268.
  • Cao Y, Jian F, Wang J, et al. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. Nature. 2022. doi:10.1038/s41586-022-05644-7
  • CDC COVID Data Tracker: Variant Proportions. 2023.
  • EG.5 Initial Risk Evaluation, 9 August 2023. 2023.
  • NextStrain. 2023.
  • Qu P, Faraone JN, Evans JP, et al. Durability of booster mRNA vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 subvariants. N Engl J Med. 2022;387:1329–1331. doi:10.1056/NEJMc2210546
  • Qu P, Evans JP, Faraone JN, et al. Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2. Cell Host Microbe. 2023;31:9–17.e13. doi:10.1016/j.chom.2022.11.012
  • Zeng C, Evans JP, Pearson R, et al. Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers, and convalescent plasma donors. JCI Insight. 2020;5; doi:10.1172/jci.insight.143213
  • San Filippo S, Crovetto B, Bucek J, et al. Comparative efficacy of early COVID-19 monoclonal antibody therapies: a retrospective analysis. Open Forum Infect Dis. 2022;9:ofac080. doi:10.1093/ofid/ofac080
  • Zeng, C., Evans, J.P., Qu, P., et al. Neutralization and stability of SARS-CoV-2 Omicron variant. bioRxiv. 2021. doi:10.1101/2021.12.16.472934.
  • Qu, P., Faraone, J.N., Evans, J.P., et al. Differential Evasion of Delta and Omicron Immunity and Enhanced Fusogenicity of SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants. bioRxiv, 2022, 2022.2005.2016.492158. doi:10.1101/2022.05.16.492158.
  • Smith DJ, Lapedes AS, de Jong JC, et al. Mapping the antigenic and genetic evolution of influenza virus. Science. 2004;305:371–376. doi:10.1126/science.1097211
  • Kaku, Y., Kosugi, Y., Uriu, K., et al. Antiviral efficacy of the SARS-CoV-2 XBB breakthrough infection sera against Omicron subvariants including EG.5. bioRxiv, 2023, 2023.2008.2008.552415. doi:10.1101/2023.08.08.552415.
  • Wang, Q., Guo, Y., Zhang, R.M., et al. Antibody neutralization of emerging SARS-CoV-2: EG.5.1 and XBC.1.6. bioRxiv, 2023, 2023.2008.2021.553968. doi:10.1101/2023.08.21.553968.
  • Cao, Y.R. Convergent evolution of SARS-CoV-2 XBB lineages on receptor-binding domain 455-456 enhances antibody evasion and ACE2 binding. bioRxiv, 2023, 2023.08.30.555211.
  • Wang, Q., Bowen, A., Ho, J., et al. SARS-CoV-2 neutralizing antibodies following a second BA.5 bivalent booster. bioRxiv, 2023, 2023.2008.2013.553148. doi:10.1101/2023.08.13.553148.
  • Chen C, Nadeau S, Yared M, et al. CoV-Spectrum: analysis of globally shared SARS-CoV-2 data to identify and characterize new variants. Bioinformatics. 2021;38:1735–1737. doi:10.1093/bioinformatics/btab856
  • Fujita S, Uriu K, Pan L, et al. Impact of imprinted immunity induced by mRNA vaccination in an experimental animal model. J Infect Dis. 2023. doi:10.1093/infdis/jiad230
  • Pfizer and BioNTech submit applications to U.S. FDA for Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine. 2023.
  • Moderna files for fda authorization of its updated COVID-19 Vaccine. 2023.
  • Will New COVID Vaccines Work Against EG.5? 2023.
  • Imai M, Ito M, Kiso M, et al. Efficacy of antiviral agents against Omicron subvariants BQ.1.1 and XBB. N Engl J Med. 2023;388:89–91. doi:10.1056/NEJMc2214302

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.